Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03970122 · ClinicalTrials.gov registry record · Phase 1
FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects
A Phase 1 study, sponsored by Goldfinch Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT03970122: Completed Phase 1 study, sponsored by Goldfinch Bio.
NCT03970122 is a Phase 1 study that has completed, run by Goldfinch Bio. The registered enrollment target is 70 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03970122, a Phase 1 study, has completed, sponsored by Goldfinch Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
The study will comprise primarily a single-ascending dose (SAD) escalation component.
Primary Outcome
Safety and tolerability
Interventions
- DRUG Placebo
- DRUG GFB-887
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2019-05-29 |
| Est. Completion | 2020-04-04 |
| Phase | Phase 1 |
What the finished NCT03970122 record still lists
NCT03970122 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03970122 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03970122 about?
NCT03970122 is a clinical study titled "FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects". The study will comprise primarily a single-ascending dose (SAD) escalation component.
What is the current status of trial NCT03970122?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2019-05-29. Estimated completion is 2020-04-04.
What interventions are being tested in trial NCT03970122?
The interventions under investigation include: Placebo (DRUG), GFB-887 (DRUG).
Who is sponsoring clinical trial NCT03970122?
This trial is sponsored by Goldfinch Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03970122's enrollment target sits among peer trials
70 749th of 2000 higher than 1,227 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI